UniProtKB/Swiss-Prot P63000: Variant p.Asn39Ser

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 39 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer: Variants classification is intended for research purposes only, not for clinical and diagnostic use. The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant.] The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Asparagine (N) to Serine (S) at position 39 (N39S, p.Asn39Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from medium size and polar (N) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In MRD48; decreased substrate adhesion-dependent cell spreading; dominant-negative effect; reduced neuronal proliferation. Any additional useful information about the variant.
Other resources: Links to websites of interest for the variant.

• Variant rs1554263624 [ dbSNP | Ensembl ]

Sequence information

Variant position: 39 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 192 The length of the canonical sequence.
Location on the sequence: LLISYTTNAFPGEYIPTVFD N YSANVMVDGKPVNLGLWDTA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 189	Ras-related C3 botulinum toxin substrate 1
Motif	32 – 40	Effector region
Modified residue	32 – 32	(Microbial infection) O-AMP-tyrosine; by Haemophilus IbpA; alternate
Modified residue	35 – 35	(Microbial infection) O-AMP-threonine; by Vibrio VopS
Glycosylation	32 – 32	(Microbial infection) O-linked (GlcNAc) tyrosine; by Photorhabdus PAU_02230; alternate
Glycosylation	35 – 35	(Microbial infection) O-alpha-linked (GlcNAc) threonine; by C.novyi toxin TcdA; alternate
Glycosylation	35 – 35	(Microbial infection) O-linked (Glc) threonine; by C.difficile toxins TcdA and TcdB, and by P.sordellii toxin TcsL; alternate
Mutagenesis	30 – 30	G -> V. No interaction with PPP5C; when associated with L-61. Translocates to the plasma membrane; also when associated with L-61.
Mutagenesis	32 – 32	Y -> F. Abolishes AMPylation by Haemophilus IbpA.
Mutagenesis	35 – 35	T -> A. Abolishes AMPylation by Vibrio VopS.
Mutagenesis	35 – 35	T -> S. No interaction with PPP5C; when associated with L-61. Translocates to the plasma membrane; also when associated with L-61.
Mutagenesis	37 – 37	F -> A. Strongly reduced interaction with PLCB2.
Mutagenesis	56 – 56	W -> A. Strongly reduced interaction with PLCB2.
Beta strand	39 – 46

Literature citations

RAC1 Missense Mutations in Developmental Disorders with Diverse Phenotypes.
Reijnders M.R.F.; Ansor N.M.; Kousi M.; Yue W.W.; Tan P.L.; Clarkson K.; Clayton-Smith J.; Corning K.; Jones J.R.; Lam W.W.K.; Mancini G.M.S.; Marcelis C.; Mohammed S.; Pfundt R.; Roifman M.; Cohn R.; Chitayat D.; Millard T.H.; Katsanis N.; Brunner H.G.; Banka S.;
Am. J. Hum. Genet. 101:466-477(2017)
Cited for: FUNCTION; INVOLVEMENT IN MRD48; VARIANTS MRD48 TYR-18; SER-39; LEU-51; MET-51; ASP-64; LEU-73 AND TYR-157; CHARACTERIZATION OF VARIANTS MRD48 TYR-18; SER-39; MET-51; ASP-64; LEU-73 AND TYR-157;